<?xml version="1.0" encoding="UTF-8"?>
<p id="para0026">Studies in STZ-induced diabetic rats showed that oral administration of 
 <bold>4</bold> and 
 <bold>5</bold> decreased plasma glucose level, glycosylated hemoglobin (HbA1c), total cholesterol (TC), TG, LDL-C and at the same time markedly increased plasma insulin, tissue glycogen and HDL-C (
 <xref rid="bib0039" ref-type="bibr">Eliza et al., 2009a</xref>, 
 <xref rid="bib0040" ref-type="bibr">2009b</xref>). The specific mechanism of eremanthin (
 <bold>4</bold>) bioactivity is not completely characterized, but the experimental model used in both works allowed the authors to suggest that this molecule might exert an insulin-like effect on peripheral tissues by either promoting glucose uptake metabolism, by inhibiting hepatic gluconeogenesis or by absorption of glucose into the muscle and adipose tissues through the stimulation of a regeneration process and revitalization of the remaining β cells (
 <xref rid="bib0039" ref-type="bibr">Eliza et al., 2009a</xref>, 
 <xref rid="bib0040" ref-type="bibr">2009b</xref>).
</p>
